Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part 2): prospective study
| Autor: | Paride Fenaroli, Enrico Verrina, Paola Migliorini, Renato Alberto Sinico, Leda Cipriani, Angelo A. Manfredi, Francesco Locatelli, Marta Mosca, Federico Pratesi, Angelo Ravelli, Marcello Bagnasco, Augusto Vaglio, Giulia Pazzola, Micaela Fredi, Andrea Petretto, Carlomaurizio Montecucco, Barbara Trezzi, Franco Franceschini, Valentina Binda, Domenico Santoro, Giacomo Garibotto, Giovanni Candiano, Marco Prunotto, Francesco Scolari, Giuseppe A. Ramirez, Giacomo Emmi, Matteo D'Alessandro, Isabella Pisani, Andrea Angeletti, Giampaola Pesce, Simone Negrini, Pasquale Esposito, Giuseppe Murdaca, Angela Tincani, Gabriella Moroni, Gian Marco Ghiggeri, Ilaria Cavazzana, Stefano Volpi, Maurizio Bruschi, Lorenzo Cavagna |
|---|---|
| Přispěvatelé: | Bruschi, M, Moroni, G, Sinico, R, Franceschini, F, Fredi, M, Vaglio, A, Cavagna, L, Petretto, A, Pratesi, F, Migliorini, P, Locatelli, F, Pazzola, G, Pesce, G, Bagnasco, M, Manfredi, A, Ramirez, G, Esposito, P, Murdaca, G, Negrini, S, Cipriani, L, Trezzi, B, Emmi, G, Cavazzana, I, Binda, V, D'Alessandro, M, Fenaroli, P, Pisani, I, Garibotto, G, Montecucco, C, Santoro, D, Scolari, F, Volpi, S, Mosca, M, Tincani, A, Candiano, G, Prunotto, M, Verrina, E, Angeletti, A, Ravelli, A, Ghiggeri, G, Bruschi, M., Moroni, G., Sinico, R. A., Franceschini, F., Fredi, M., Vaglio, A., Cavagna, L., Petretto, A., Pratesi, F., Migliorini, P., Locatelli, F., Pazzola, G., Pesce, G., Bagnasco, M., Manfredi, A., Ramirez, G. A., Esposito, P., Murdaca, G., Negrini, S., Cipriani, L., Trezzi, B., Emmi, G., Cavazzana, I., Binda, V., D'Alessandro, M., Fenaroli, P., Pisani, I., Garibotto, G., Montecucco, C., Santoro, D., Scolari, F., Volpi, S., Mosca, M., Tincani, A., Candiano, G., Prunotto, M., Verrina, E., Angeletti, A., Ravelli, A., Ghiggeri, G. M. |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Male Anti-nuclear antibody Lupus nephritis lupus nephriti Gastroenterology Histones 0302 clinical medicine systemic lupus erythematosus anti-C1q antibodie Lupus Erythematosus Systemic Pharmacology (medical) Prospective Studies Prospective cohort study AcademicSubjects/MED00360 Annexin A1 anti-ENO1 antibodie education.field_of_study Keywords: anti-C1q antibodies anti-ENO1 antibodies anti-Histone 2A antibodies biomarkers lupus nephritis Proteinuria biology anti-C1q antibodies Adult Antibodies Antinuclear Autoantibodies Biomarkers Tumor Complement C1q DNA DNA-Binding Proteins Disease Progression Female Humans Immunoglobulin G Lupus Nephritis Middle Aged Nucleosomes Phosphopyruvate Hydratase Tumor Suppressor Proteins Clinical Science biomarker medicine.symptom medicine.medical_specialty anti-Histone 2A antibodie Population Renal function systemic lupus erythematosu 03 medical and health sciences Rheumatology Internal medicine medicine education 030203 arthritis & rheumatology business.industry Anti-dsDNA antibodies Autoantibody medicine.disease 030104 developmental biology biology.protein business |
| Zdroj: | Rheumatology (Oxford, England) |
| Popis: | Objectives Circulating anti-ENO1 and anti-H2A IgG2 have been identified as specific signatures of LN in a cross-over approach. We sought to show whether the same antibodies identify selected population of patients with LN with potentially different clinical outcomes. Methods Here we report the prospective analysis over 36 months of circulating IgG2 levels in patients with newly diagnosed LN (n=91) and SLE (n=31) and in other patients with SLE recruited within 2 years from diagnosis (n=99). Anti-podocyte (ENO1), anti-nucleosome (DNA, histone 2 A, histone 3) and anti-circulating proteins (C1q, AnnexinA1-ANXA1) IgG2 antibodies were determined by home-made techniques. Results LN patients were the main focus of the study. Anti-ENO1, anti-H2A and anti-ANXA1 IgG2 decreased in parallel to proteinuria and normalized within 12 months in the majority of patients while anti-dsDNA IgG2 remained high over the 36 months. Anti-ENO1 and anti-H2A had the highest association with proteinuria (Heat Map) and identified the highest number of patients with high proteinuria (68% and 71% respectively) and/or with reduced estimated glomerula filtration rate (eGFR) (58% for both antibodies) compared with 23% and 17% of anti-dsDNA (agreement analysis). Anti-ENO1 positive LN patients had higher proteinuria than negative patients at T0 and presented the maximal decrement within 12 months. Conclusions Anti-ENO1, anti-H2A and anti-ANXA1 antibodies were associated with high proteinuria in LN patients and Anti-ENO1 also presented the maximal reduction within 12 months that paralleled the decrease of proteinuria. Anti-dsDNA were not associated with renal outcome parameters. New IgG2 antibody signatures should be utilized as tracers of personalized therapies in LN. Trial registration The Zeus study was registered at https://clinicaltrials.gov (study number: NCT02403115). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|